This study is for people who have kidney cancer, also called renal cell carcinoma (RCC), and have already had surgery to remove the cancer. The study tests if adding a medicine called *tivozanib* to another medicine, *pembrolizumab*, can help stop the cancer from coming back. Pembrolizumab is an immunotherapy that helps your body fight cancer cells, while tivozanib blocks proteins that help cancer cells grow. **Key Points:** - The study lasts up to 2 years, with medicine cycles every 12 weeks. - You'll need regular visits for blood tests and scans (MRI or CT). - You may have side effects, and you'll be closely monitored for safety. To join, you must be 18+, with certain health conditions, and no previous RCC treatments. You'll be randomly placed in one of two groups: either getting both pembrolizumab and tivozanib or just pembrolizumab. After treatment, follow-ups continue for several years. This trial helps researchers understand if adding tivozanib can improve treatment outcomes for kidney cancer patients.